通用名和剂型：
地高辛0.0625mg ， 0.125 + 0.1875mg ，为0.25mg + （+）拿下了标签。
公司名称：
Covis制药公司
【适应症】用于LANOXIN ：
轻度至中度心脏衰竭（具有利尿和ACE抑制剂可能的话） 。控制心室率在慢性房颤。
成人和儿童剂量：
个性：见文献。剂量减少早产和未成熟儿。儿童通常需要按比例较大剂量（根据体重或表面积）比成人。采用分次服用儿童< 10yrs 。改变配方时（尤其是口服片或其他剂型）返滴定。
另请参见：
LANOXIN注射
LANOXIN注射小儿
药理分类：
强心苷。
禁忌症：
心室颤动。
警告/注意事项：
肾功能不全：减少剂量。窦房结疾病。不完全房室传导阻滞。配件影音通路（预激综合征） 。心脏衰竭与保存左心室射血分数（例如，限制型心肌病，缩窄性心包炎，心脏淀粉样蛋白病，急性肺心病，特发性肥厚性主动脉瓣下狭窄） 。电复律。急性心肌梗死。毒性风险增加低钾血症，低镁血症，高钙血症。低钙血症可能抵消作用。甲状腺疾病。高代谢状态。监控地高辛水平，电解质，肾功能。早产儿。新生儿。怀孕（ Cat.C ） 。哺乳期的母亲。
互动：
毒性风险增加钾消耗的药物（如利尿剂，两性霉素B ，皮质类固醇） 。地高辛水平增加了抗生素（如大环内酯类，四环素类） ，胺碘酮，普罗帕酮，奎尼丁，异搏定，吲哚美辛，伊曲康唑，阿普唑仑，安体舒通，药物，减少胃肠道蠕动（如普鲁本辛，地芬诺酯） ，甲状腺拮抗剂，药物，可以降低肾功能。地高辛水平降低了甲状腺激素，抗酸剂，高岭土，果胶，消胆胺，利福平，柳氮磺胺吡啶，新霉素，药物，增加胃肠道蠕动（如胃复安） ，一些抗肿瘤药物。地高辛水平可能受奎宁，青霉胺，非洛地平，等等。心律失常与交感神经，琥珀胆碱，或快速钙滴注。用的药物，影响心脏传导（例如，钙通道阻滞剂，β-阻滞剂）的心脏传导阻滞。
不良反应：
胃肠道不适，厌食，中枢神经系统的影响（例如，视力模糊或视力黄色，或精神障碍，精神错乱，头痛，乏力，头晕，冷漠） ，男子女性型乳房，皮疹，心脏传导阻滞，心律失常（特别是儿童）。
如何提供：
标签- 100 ， 1000;进样0.25mg/mL （ 2毫升放大器） -10 ， 50 ，进样儿科（ 1毫升放大器） -10
Generic Name and Formulations:
Digoxin 0.0625mg, 0.125mg+, 0.1875mg, 0.25mg+; (+) scored tabs.
Company:
Covis Pharmaceuticals, Inc.
Indications for LANOXIN:
Mild-to-moderate heart failure (with a diuretic and an ACE inhibitor when possible). Control of ventricular response rate in chronic atrial fibrillation.
Adults and Children's Dose:
Individualize: see literature. Reduce dose in premature and immature infants. Children usually need proportionally larger doses (based on body weight or surface area) than adults. Use divided doses for children <10yrs. Retitrate when changing formulations (esp. oral tabs to or from other dose forms).
See Also:
LANOXIN INJECTION
LANOXIN INJECTION PEDIATRIC
Pharmacological Class:
Cardiac glycoside.
Contraindications:
Ventricular fibrillation.
Warnings/Precautions:
Renal dysfunction: reduce dose. Sinus node disease. Incomplete AV block. Accessory AV pathway (Wolff-Parkinson-White syndrome). Heart failure with preserved LV ejection fraction (eg, restrictive cardiomyopathy, constrictive pericarditis, amyloid heart disease, acute cor pulmonale, idiopathic hypertrophic subaortic stenosis). Electrical cardioversion. Acute MI. Toxicity risk increased by hypokalemia, hypomagnesemia, hypercalcemia. Hypocalcemia may nullify effects. Thyroid disease. Hypermetabolic states. Monitor digoxin levels, electrolytes, renal function. Premature infants. Neonates. Pregnancy (Cat.C). Nursing mothers.
Interactions:
Toxicity risk increased by potassium-depleting drugs (eg, diuretics, amphotericin B, corticosteroids). Digoxin levels increased by antibiotics (eg, macrolides, tetracyclines), amiodarone, propafenone, quinidine, verapamil, indomethacin, itraconazole, alprazolam, spironolactone, drugs that reduce GI motility (eg, propantheline, diphenoxylate), thyroid antagonists, drugs that reduce renal function. Digoxin levels decreased by thyroid hormones, antacids, kaolin-pectin, cholestyramine, rifampin, sulfasalazine, neomycin, drugs that increase GI motility (eg, metoclopramide), some antineoplastics. Digoxin levels possibly affected by quinine, penicillamine, felodipine, others. Arrhythmias with sympathomimetics, succinylcholine, or rapid calcium infusion. Heart block with drugs that affect cardiac conduction (eg, calcium channel blockers, β-blockers).
Adverse Reactions:
GI upset, anorexia, CNS effects (eg, blurred or yellow vision, or mental disturbances, confusion, headache, weakness, dizziness, apathy), gynecomastia, rash, heart block, arrhythmias (esp. children).
How Supplied:
Tabs—100, 1000; Inj 0.25mg/mL (2mL amps)—10, 50; Inj Pediatric (1mL amp)—10